Objective: To investigate the effect of cerebral circulation function therapy device combined with aripiprazole on cognitive and social function in female patients with schizophrenia (SCH). Methods: A total of 140 female patients with SCH admitted to the Department of Mental Diseases of the Affiliated Hospital of Wanxi Health Vocational College from June 2019 to May 2021 were selected and randomly divided into a drug group and a combined group by random number table method, with 70 cases in each group. The drug group was given aripiprazole monotherapy, and the combined group was treated with cerebral circulation function therapy device combined with aripiprazole for 6 weeks. The scores of Positive and Negative Symptom Scale (PANSS), clinical efficacy, MATRICS Consensus Cognitive Battery (MCCB), and Personal and Social Function Scale (PSP) were compared between the two groups. Results: After 6 weeks of treatment, the total scores of PANSS and three subscales in the two groups decreased compared with those before treatment (P<0.05). The positive symptoms, general psychopathological symptoms and total scores of PANSS in the combined group were lower than those in the drug group, and the total effective rate was higher than that in the drug group (all P<0.05). After 6 weeks of treatment, the scores of each cognitive domain of MCCB in the two groups were higher than those before treatment (P<0.05). The scores of working memory, speech learning and memory, reasoning and problem-solving ability, and social cognition in the combined group were higher than those in the drug group (P<0.05). After 6 weeks of treatment, the PSP score in the combined group was higher than that before treatment (P<0.05), and it was also significantly higher than that in the drug group (P<0.05). Conclusion: Cerebral circulatory system therapeutic instrument combined with aripiprazole can not only significantly reduce PANSS score in patients with Sch, but also help to improve cognitive and social function.